Medicaid Managed Care Open Enrollment Extended through Dec. 15
Current Suspected Overdose Deaths in Delaware for 2017: 227
The Delaware Division of Public Health is issuing this health alert to provide healthcare providers and facilities with details regarding additional contaminated medical products identified in the ongoing Food and Drug Administration (FDA) investigation associated with the fungal meningitis outbreak. It is unknown whether facilities in Delaware received the lots of contaminated betamethasone or cardioplesia solution.
The Centers for Disease Control and Prevention (CDC) and FDA are reporting that product testing has identified bacterial contamination with several Bacillus species and closely related bacterial organisms in unopened vials of betamethasone and cardioplegia solution that were distributed and later recalled by NECC on October 6, 2012. These bacteria are commonly found in the environment and have been rarely reported as a cause of human disease; it is not known how product contamination with these species might affect patients. CDC has not received reports of laboratory-confirmed cases of infection due to Bacillus or closely related organisms linked to these products.
The following table provides CDC and FDA laboratory testing results for contamination and product lot numbers. Other cultures for these products, including fungal cultures, are pending.
|Medication||Lot number||Microbial contamination|
|Betamethasone||08202012@141||Paenibacillus pabuli/amolyticus, Bacillus idriensis, Bacillus flexus, Bacillus simplex, Lysinibacillus sp.|
|Betamethasone||07032012@22||Bacillus niabensis, Bacillus circulans|
|Betamethasone||07302012@52||Bacillus lentus, Bacillus circulans|
|Cardioplegia solution||09242012@55||Bacillus halmapalus, Brevibacillus choshinensis|
You are receiving this message because you are a registered member of the Delaware Health Alert Network. If you are not a member and would like to subscribe, please register at https://healthalertde.org